Shares of Onconova Therapeutics Inc (NASDAQ:ONTX) have received a consensus rating of “Buy” from the six research firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $9.00.
A number of brokerages recently weighed in on ONTX. ValuEngine raised Onconova Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 14th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Onconova Therapeutics in a research note on Friday, March 9th. Maxim Group reissued a “hold” rating on shares of Onconova Therapeutics in a research note on Thursday, March 8th. Finally, Zacks Investment Research raised Onconova Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th.
Shares of Onconova Therapeutics stock traded down $0.08 during mid-day trading on Thursday, hitting $0.93. The company had a trading volume of 719,481 shares, compared to its average volume of 598,243. Onconova Therapeutics has a 1-year low of $0.90 and a 1-year high of $3.88. The company has a market cap of $17.67, a P/E ratio of -0.33 and a beta of 0.22.
In other Onconova Therapeutics news, major shareholder 683 Capital Management, Llc purchased 200,000 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were bought at an average cost of $1.04 per share, with a total value of $208,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 13.30% of the company’s stock.
An institutional investor recently raised its position in Onconova Therapeutics stock. 683 Capital Management LLC boosted its holdings in Onconova Therapeutics Inc (NASDAQ:ONTX) by 24.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 464,934 shares of the biopharmaceutical company’s stock after buying an additional 89,934 shares during the period. 683 Capital Management LLC owned approximately 4.32% of Onconova Therapeutics worth $697,000 as of its most recent SEC filing. 12.72% of the stock is currently owned by hedge funds and other institutional investors.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.